Giant cell tumor (GCT) is a rare complication of Paget's bone disease (PBD). Previous reports have suggested that urokinase-type plasminogen activation system may play a role in local invasion and growth of GCT. Since glucocorticoids induce the expression of the plasminogen activator inhibitor type I (PAI-1) and suppress the activity of both the urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) we implied that the therapeutic effects of glucocorticoids on GCT depend on the modulation of the PA-PAI system. Therefore we have evaluated PAI-1 plasma levels in a patient with familial PBD and GCT. We observed significant reduction of PAI-1 plasma levels after bisphosphonate treatment and complete normalization during dexamethasone treatment. These data suggest the involvement of PA-PAI-1 system in pathogenesis of PBD and GCT and disclose a new scenario for the understanding of genetic basis of PBD.
Effects of gluocorticoid therapy in giant cell tumor associated with Paget's bone disease. A possible role of the PAI-PA system / Ronca, M.; Vuotto, P.; Rendina, D.; Ciccarelli, P. R.; Numis, F. G.; Mossetti, G.; De Caterina, M.; Scopacasa, F.; Nunziata, V.. - In: ITALIAN JOURNAL OF MINERAL & ELECTROLYTE METABOLISM. - ISSN 1121-1709. - 13:3-4(1999), pp. 45-47.
Effects of gluocorticoid therapy in giant cell tumor associated with Paget's bone disease. A possible role of the PAI-PA system
Rendina D.;Mossetti G.;De Caterina M.;Scopacasa F.;Nunziata V.
1999
Abstract
Giant cell tumor (GCT) is a rare complication of Paget's bone disease (PBD). Previous reports have suggested that urokinase-type plasminogen activation system may play a role in local invasion and growth of GCT. Since glucocorticoids induce the expression of the plasminogen activator inhibitor type I (PAI-1) and suppress the activity of both the urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) we implied that the therapeutic effects of glucocorticoids on GCT depend on the modulation of the PA-PAI system. Therefore we have evaluated PAI-1 plasma levels in a patient with familial PBD and GCT. We observed significant reduction of PAI-1 plasma levels after bisphosphonate treatment and complete normalization during dexamethasone treatment. These data suggest the involvement of PA-PAI-1 system in pathogenesis of PBD and GCT and disclose a new scenario for the understanding of genetic basis of PBD.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
